U
ACUR

UBS’s Acura Pharmaceuticals ACUR Stock Holding History

UBS’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-320
Closed -$3K – 11074
2013
Q3 		$3K Buy
+320
New +$2.83K ﹤0.01% 9841

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

UBS's ACUR Position: Q3 2014 in Review

UBS opened a new position in Acura Pharmaceuticals (ACUR) in Q3 2014: 563 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #10075 among its holdings. This is a return to the name: UBS previously reported a position in ACUR as recently as Q4 2013.

UBS first reported a position in ACUR in Q2 2013 and has held it in 4 quarters since. The position peaked at $40K in Q4 2013. 28 funds tracked by Wall St. Rank hold ACUR as of Q3 2014.

  • UBS held 563 shares of Acura Pharmaceuticals worth $2K as of Q3 2014.
  • Acura Pharmaceuticals was a new UBS position in Q3 2014.
  • Acura Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10075 holding.
  • UBS first reported a position in Acura Pharmaceuticals in Q2 2013 and has held it in 4 quarters since.
  • UBS's Acura Pharmaceuticals position peaked at $40K in Q4 2013.
  • 28 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.